AsclepiX Therapeutics, Inc., a biopharmaceutical company focused on developing novel peptide therapies, including AXT107 for retinal disease and novel peptides for cancer, adds Steven Altschuler, MD to Board of Directors.
Dr. Altschuler, the founder and Chairman of the Board of Spark TherapeuticsInc. (NASDAQ: ONCE), brings to AsclepiX a deep knowledge and experience in developing novel therapies for the treatment of retinal disease.
AXT107 exhibited a dual mechanism of action as a monotherapy, disrupting a key component of the Vascular Endothelial Growth Factor (VEGF) signaling pathway while also activating the Tie2 pathway that is integral to maintenance of vascular homeostasis.
A single monotherapy injection of AXT107 demonstrated in vivo efficacy lasting for many months, suggesting patients may require only 1 to 2 injections per year.
To date, AXT107 has demonstrated excellent safety, superior efficacy and longer durability in in vivo models compared to current standard of care treatments.